Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2

Audrey Rousseau, Catherine L. Nutt, Rebecca Betensky, A. John Iafrate, Moonjoo Han, Keith L. Ligon, David H. Rowitch, David N. Louis

Research output: Contribution to journalArticle

Abstract

The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes. Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas. For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant. GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively). Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas. In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.

Original languageEnglish (US)
Pages (from-to)1149-1156
Number of pages8
JournalJournal of Neuropathology and Experimental Neurology
Volume65
Issue number12
DOIs
StatePublished - Jan 1 2006

Fingerprint

Oligodendroglioma
Astrocytoma
Apolipoproteins E
Glioma
Glioblastoma
Neuroglia
Tumor Biomarkers
Immunohistochemistry
Population
Neoplasms

Keywords

  • ApoE
  • ASCL1
  • Astrocytoma
  • Immunohistochemistry
  • NKX2-2
  • Oligodendroglioma
  • YKL-40

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas : Use of YKL-40, ApoE, ASCL1, and NKX2-2. / Rousseau, Audrey; Nutt, Catherine L.; Betensky, Rebecca; Iafrate, A. John; Han, Moonjoo; Ligon, Keith L.; Rowitch, David H.; Louis, David N.

In: Journal of Neuropathology and Experimental Neurology, Vol. 65, No. 12, 01.01.2006, p. 1149-1156.

Research output: Contribution to journalArticle

Rousseau, Audrey ; Nutt, Catherine L. ; Betensky, Rebecca ; Iafrate, A. John ; Han, Moonjoo ; Ligon, Keith L. ; Rowitch, David H. ; Louis, David N. / Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas : Use of YKL-40, ApoE, ASCL1, and NKX2-2. In: Journal of Neuropathology and Experimental Neurology. 2006 ; Vol. 65, No. 12. pp. 1149-1156.
@article{1264e303cfe7404e85f90dbcf459085c,
title = "Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2",
abstract = "The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes. Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas. For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant. GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively). Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas. In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.",
keywords = "ApoE, ASCL1, Astrocytoma, Immunohistochemistry, NKX2-2, Oligodendroglioma, YKL-40",
author = "Audrey Rousseau and Nutt, {Catherine L.} and Rebecca Betensky and Iafrate, {A. John} and Moonjoo Han and Ligon, {Keith L.} and Rowitch, {David H.} and Louis, {David N.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1097/01.jnen.0000248543.90304.2b",
language = "English (US)",
volume = "65",
pages = "1149--1156",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas

T2 - Use of YKL-40, ApoE, ASCL1, and NKX2-2

AU - Rousseau, Audrey

AU - Nutt, Catherine L.

AU - Betensky, Rebecca

AU - Iafrate, A. John

AU - Han, Moonjoo

AU - Ligon, Keith L.

AU - Rowitch, David H.

AU - Louis, David N.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes. Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas. For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant. GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively). Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas. In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.

AB - The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes. Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas. For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant. GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively). Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas. In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.

KW - ApoE

KW - ASCL1

KW - Astrocytoma

KW - Immunohistochemistry

KW - NKX2-2

KW - Oligodendroglioma

KW - YKL-40

UR - http://www.scopus.com/inward/record.url?scp=33845394445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845394445&partnerID=8YFLogxK

U2 - 10.1097/01.jnen.0000248543.90304.2b

DO - 10.1097/01.jnen.0000248543.90304.2b

M3 - Article

C2 - 17146289

AN - SCOPUS:33845394445

VL - 65

SP - 1149

EP - 1156

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 12

ER -